<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7607088</journal-id>
<journal-id journal-id-type="pubmed-jr-id">673</journal-id>
<journal-id journal-id-type="nlm-ta">Annu Rev Pharmacol Toxicol</journal-id>
<journal-id journal-id-type="iso-abbrev">Annu. Rev. Pharmacol. Toxicol.</journal-id>
<journal-title-group>
<journal-title>Annual review of pharmacology and toxicology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0362-1642</issn>
<issn pub-type="epub">1545-4304</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30256716</article-id>
<article-id pub-id-type="pmc">6538038</article-id>
<article-id pub-id-type="doi">10.1146/annurev-pharmtox-010818-021856</article-id>
<article-id pub-id-type="manuscript">NIHMS1027349</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Modulating NRF2 in disease: Timing is everything</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dodson</surname>
<given-names>Matthew</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de la Vega</surname>
<given-names>Montserrat Rojo</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cholanians</surname>
<given-names>Aram B.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schmidlin</surname>
<given-names>Cody J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chapman</surname>
<given-names>Eli</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Donna D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA, 85721</aff>
<aff id="A2"><label>2</label>Arizona Cancer Center, University of Arizona, Tucson, AZ, USA, 85724</aff>
<author-notes>
<corresp id="CR1"><label>*</label>To whom correspondence should be addressed: Dr. Donna D. Zhang, College of Pharmacy, 1703 East Mabel Street, Tucson, AZ, 85721, <email>dzhang@pharmacy.arizona.edu</email>, Phone number: 520-626-9918</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>16</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<day>06</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>06</day>
<month>10</month>
<year>2019</year>
</pub-date>
<volume>59</volume>
<fpage>555</fpage>
<lpage>575</lpage>
<!--elocation-id from pubmed: 10.1146/annurev-pharmtox-010818-021856-->
<abstract id="ABS1">
<p id="P1">The transcription factor nuclear factor erythroid-2 (NF-E2)-related factor 2 (NRF2) is a central regulator of redox, metabolic, and protein homeostasis that intersects with many other signaling cascades. While the understanding of the complex nature of NRF2 signaling continues to grow, there is only one therapeutic targeting NRF2 for clinical use, dimethyl fumarate, used for the treatment of multiple sclerosis. The discovery of new therapies is confounded by the fact that NRF2 levels vary significantly depending on physiological and pathological context. Thus, properly timed and targeted manipulation of the NRF2 pathway is critical in creating effective therapeutic regimens. In this review, we summarize the regulation and downstream targets of NRF2. Furthermore, we discuss the role of NRF2 in cancer, neurodegeneration, and diabetes, as well as cardiovascular, kidney, and liver disease, with a special emphasis on NRF2-based therapeutics, including those that have made it into clinical trials.</p>
</abstract>
<kwd-group>
<kwd>NRF2</kwd>
<kwd>KEAP1</kwd>
<kwd>therapeutics</kwd>
<kwd>cancer</kwd>
<kwd>disease</kwd>
<kwd>clinical trials</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>